



CASE BP/G-32575A

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV 786957237

Express Mail Label Number

5 | 31 | 2007

Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

BETZ ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP03/07349

FILED: 8 JULY 2003

U.S. APPLICATION NO: 10/520,568 ✓

35 USC §371 DATE:

FOR: LIQUID FORMULATIONS WITH HIGH CONCENTRATION OF
HUMAN GROWTH HORMONE (HGH) COMPRISING 1,2-
PROPYLENE GLYCOL

MS: Amendment

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:


This paper is supplemental to the Information Disclosure Statement filed January 7, 2005. Since Applicants believe this paper is being filed before the mailing date of a first Office Action on the merits, no fees are believed to be required under 37 C.F.R. §1.97(b)(3). If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Mark Bowditch", is written over a horizontal line.

Mark Bowditch
Attorney for Applicants
Reg. No. 40,315

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(609) 627-8507

Date: 5/31/2007

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
BP/G-32575A
APPLICATION NO.
10/520,568
APPLICANT
BETZ ET AL.
FILING DATE

Group



U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	5,597,802	1/28/97	Clark et, al.			
	AB	4,857,505	8/15/89	Volker D. Arendt			
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	EP 0 303 746	2/22/89	International Minerals			<input type="checkbox"/>	<input type="checkbox"/>
	AN	EP 0 211 601	7/29/86	International Minerals			<input type="checkbox"/>	<input type="checkbox"/>
	AO	AU A-60733/86	2/5/87	International Minerals Corp			<input type="checkbox"/>	<input type="checkbox"/>
	AP	WO 1991/14454	4/2/91	Skua Investments Ltd			<input type="checkbox"/>	<input type="checkbox"/>
	AQ	AU A-611856	9/5/90	Chungai Seiyaku			<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AR	Physicians Desk Reference, PDR 43, 1989 Edition 989-990
AS	Peter Goddard, " Therapeutic proteins- a Pharmaceutical perspective", 1990, pgs103-131
AT	Isosmotic and Isotonic Solutions, pgs 521-526

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
BP/G-32575A
APPLICATION NO.
10/520,568
APPLICANT
BETZ ET AL.
FILING DATE

Group



U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	BA						
	BB						
	BC						
	BD						
	BE						
	BF						
	BG						
	BH						
	BI						
	BJ						
	BK						
	BL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	BM	WO 1989/02751	9/26/88	Cetus Corporation			<input type="checkbox"/>	<input type="checkbox"/>
	BN	WO 1991/11200	8/8/91	Janssen Pharma			<input type="checkbox"/>	<input type="checkbox"/>
	BO	WO 1995/28174	3/30/95	Genentech, Inc			<input type="checkbox"/>	<input type="checkbox"/>
	BP						<input type="checkbox"/>	<input type="checkbox"/>
	BQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	BR	Thurrow " Stabilisation of dissolved proteins against denaturation at hydrophobic interfaces", 1984, Diabetologica, pgs 212-218
	BS	Attar S. Chawla" Aggregation of Insulin, containing surfactants, in contact with different materials", pgs 420-424
	BT	Physicians Desk Reference, PDR 39, Edition 1985, pgs 1940-1941

EXAMINER

DATE CONSIDERED


*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
BP/G-32575A
APPLICATION NO.
10/520,568
APPLICANT
BETZ ET AL.
FILING DATE

Group



EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	DA	Journal of Parenteral Science and Technology , Technical Report 10 " Parenteral Formulations of Proteins and Peptides: Stability and Stabilizers", 1988, pgs 2-26
	DB	
	DC	
	DD	
	DE	
	DF	
	DG	
	DH	
	DI	
	DJ	
	DK	
	DL	
	DM	
	DN	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.